Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoViricides

Taiwan Semiconductor Manufacturing

The global nanotechnology market could exceed $125 billion by 2024, as it continues to impact technology, energy, defense, and even food.

3 Nanotech Stocks for Big Growth

Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.

Thermo Fisher (TMO) Partners With CSL to Expand Pharma Arm

WALTHAM, Mass. and KING OF PRUSSIA, Penn., May 27, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited (ASX:CSL;USOTC:CSLLY) today announced they have entered into a strategic partnership to help...

Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

Why Is Thermo Fisher (TMO) Up 4.8% Since Last Earnings Report?

HAUPPAUGE, N.Y., May  18, 2020  (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has signed a multi-year, non‑exclusive agreement with Thermo Fisher Scientific’s healthcare channel, to  distribute  Chembio’s DPP COVID-19 System in the United States. The DPP COVID‑19 System is a rapid serological test and analyzer that provides numerical readings for both IgM and IgG antibody levels within 15 minutes from a finger stick drop of blood. The DPP COVID‑19 System can include either Chembio’s Micro Reader 1 or Micro Reader 2 analyzer.

Chembio Diagnostics Announces US Distribution Agreement to Expand Reach of DPP COVID-19 Serological Test with Thermo Fisher Scientific’s Healthcare Channel

QIAGEN

WALTHAM, Mass., May 18, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today published the offer document (the "Offer Document") for its voluntary tender offer (the "Tender Offer") for all of the ordinary shares of QIAGEN N.V. (NYSE:...

Thermo Fisher Scientific Publishes Offer Document for Voluntary Tender Offer for All Ordinary Shares of QIAGEN N.V.

Its new test that will detect two types of SARS-CoV-2 antibodies will run on an open instrument platform.

Thermo Fisher to Turn Coronavirus Antibody Testing on Its Head

Thermo Fisher Scientific said Wednesday it plans to develop a coronavirus test to detect prior infections, known as an antibody test.

Covid Report: Medical Stock Expands Testing; Sanofi Pledges Vaccine To U.S.

Thermo Fisher Scientific (NYSE: TMO) shares are trading higher on Wednesday. The company announced it plans to develop a coronavirus antibodies test in collaboration with WuXi and Mayo Clinic.

Why Thermo Fisher's Stock Is Trading Higher Today

Thermo Fisher only modestly underperformed company guidance in Q1 as its products for testing and researching COVID-19 helped offset reduced demand from shutdowns.

Thermo Fisher Scientific: Ammo For The COVID-19 War

Thermo Fisher Scientific Inc.'s (TMO) CEO Marc Casper on Q1 2020 Results - Earnings Call Transcript

The healthcare giant's COVID-19 efforts are helping it weather the storm.

Here's How Thermo Fisher Scientific Beat Wall Street Expectations in Q1

On coronavirus-led global supply chain disruption, Thermo Fisher (TMO) records a decline in its quarterly Analytical Instruments revenues.

Thermo Fisher (TMO) Q1 Earnings Top, Life Sciences Sales Grow

Thermo Fisher (TMO) delivered earnings and revenue surprises of 5.38% and 0.38%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Surpass Estimates

Analytical instruments company Thermo Fisher Scientific Inc. TMO, -2.30% reported Wednesday first-quarter profit and revenue that topped expectations, as revenue beats in its laboratory products, specialty diagnostics and life sciences segments offset a miss in analytical instruments.

Thermo Fisher profit and revenue rise above expectations

Thermo Fisher (TMO) successfully attains EUA from the FDA as well as receives the CE Mark in Europe for its COVID-19 diagnostic test.

Will Coronavirus Test Aid Thermo Fisher's (TMO) Q1 Earnings?

Abbott Labs

Quest Diagnostics

Labcorp Holdings Inc

Roche Holding AG

Diagnostic laboratories, rather than the test manufacturers, may be the biggest beneficiaries.

Good News for COVID-19 Testing Companies: Medicare Nearly Doubles Reimbursement

Ford Motor Company

Ford (F) is also working with Joyson Safety Systems to produce reusable gowns for healthcare workers.

Ford (F) & Thermo Fisher to Produce COVID-19 Testing Kits

Ford has expanded its plan to make critical medical equipment and supplies, including a new effort to make reusable gowns from airbag materials as well as a partnership with scientific instrument provider Thermo Fisher Scientific to ramp up production of COVID-19 collection kits to test for the virus. This broader plan highlights the latest effort […]

Ford partners with Thermo Fisher on COVID-19 test kits, expands production to face masks, gowns

Becton, Dickinson and Co.

Hologic

Henry Schein

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols,  resource allocation and drafting the right healthcare policies.

Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress

Shares of Thermo Fisher Scientific Inc. TMO, -1.85% rallied 2.8% in premarket trading Monday, after the provider of analytical instruments and services for research and diagnostics provided an upbeat update to first-quarter sales.

Thermo Fisher provides upbeat first-quarter revenue growth outlook, stock rallies

Cardinal Health

IDEXX Laboratories

McKesson

Here are a few MedTech companies which have outperformed the S&P 500 index in the past two months.

Coronavirus Hits S&P 500: 4 MedTech Stocks That Fared Better

SPDR S&P Health Care Equipment ETF

A growing demand for COVID-19 tests has indulged major healthcare place in the race to develop competent testing kits.

Healthcare ETFs Gain on Rising Demand for COVID-19 Tests

While the market bloodbath is showing no signs of dissipating any time soon, investors might keep an eye on certain genetic testing and medical device companies.

4 Stocks Countering Coronavirus Battle With Testing Kits

PerkinElmer

These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.

News for Thermo Fisher Scientific Stock (TMO)